Positive results reported for anti-interleukin-6 agent for uveitis
By Cheryl Guttman Krader
Las Vegas—Intravenous administration of the anti-interleukin-6 (IL-6) agent tocilizumab (Actemra, Genentech) is well-tolerated in patients with non-infectious uveitis involving the posterior segment and showing promising efficacy, according to interim outcomes reported by Quan Dong Nguyen, MD.
Speaking at the 2015 meeting of the American Academy of Ophthalmology, a total of 37 patients were entered at 5 sites across the United States into the investigator-sponsored study known as STOP-UVEITIS.
Patients were randomly assigned to receive tocilizumab 4 or 8 mg/kg. Treatment was initiated with 6 mandatory infusions at 1-month intervals. The primary endpoint was assessed at 6 months, and then tocilizumab administration was changed to an “as needed” basis.